Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Complicated intra-abdominal infections Condition: In combination with metronidazole |
Dose: Intravenous – 2.5 g (2 g/0.5 g) Frequency: every 8 hours Duration: 5-14 days Note: Infused over 2 hours. Caused by susceptible gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae, Klebsiella oxytoca, Citrobacter freundii complex, and Pseudomonas aeruginosa. |
|
Indication: Complicated urinary tract infections Condition: Including pyelonephritis |
Dose: Intravenous – 2.5 g (2 g/0.5 g) Frequency: every 8 hours Duration: 7-14 days Note: Infused over 2 hours. Caused by susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter koseri, Enterobacter aerogenes, Enterobacter cloacae, Citrobacter freundii, Proteus mirabilis, and Pseudomonas aeruginosa. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Complicated intra-abdominal infections Age: 3 to less than 6 months |
Dose: Intravenous – 50 mg/kg (ceftazidime 40 mg/kg and avibactam 10 mg/kg) Frequency: every 8 hours Duration: 5-14 days Note: Indicated in combination with metronidazole for complicated intra-abdominal infections caused by susceptible gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae, Klebsiella oxytoca, Citrobacter freundii complex, and Pseudomonas aeruginosa |
|
Indication: Complicated intra-abdominal infections Age: 6 months to less than 2 years |
Dose: Intravenous – 62.5 mg/kg (ceftazidime 50 mg/kg and avibactam 12.5 mg/kg) Frequency: every 8 hours Duration: 5-14 days Note: Indicated in combination with metronidazole for complicated intra-abdominal infections caused by susceptible gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae, Klebsiella oxytoca, Citrobacter freundii complex, and Pseudomonas aeruginosa |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Adult Condition: Renal impairment with Creatinine Clearance greater than 50 mL/min |
Dose: Intravenous – No dose adjustment required Note: Standard dosing applies |
|
Age: Adult Condition: Renal impairment with Creatinine Clearance 31-50 mL/min |
Dose: Intravenous – 1.25 grams (1 gram/0.25 grams) Frequency: every 8 hours |
Administration
- First step: - Mix with 10mL sterile water/saline - Gently mix until clear
- Second step: - Dilute to 50-250mL total - Solution should be clear/light yellow
Side Effect
- Diarrhea (8%)
- Nausea (7%)
- Vomiting (5%)
- Headache (3%)
- Dizziness (2%)
- Abdominal pain (1%)
- Diarrhea (3%)
- Nausea (3%)
- Constipation (2%)
- Upper abdominal pain (1%)
- Nausea (3%)
- Pruritus (2%)
- Thrombocytopenia
- thrombocytosis
- leukopenia
- Injection site phlebitis
- Candidiasis
- Increased aspartate aminotransferase
- increased alanine aminotransferase
- increased gamma-glutamyltransferase
- Hypokalemia
- Dysgeusia
- Acute kidney injury
- renal impairment
- nephrolithiasis
- Rash
- rash maculopapular
- urticaria
- Anxiety
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
No interactions listed
|
-
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Serious hypersensitivity
|
Can cause severe allergic reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.